{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:14:45Z","timestamp":1785766485167,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Sanwa Kagaku Kenkyusho CO., LTD.","award":["No"],"award-info":[{"award-number":["No"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10157-019-01829-z","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T09:05:31Z","timestamp":1576487131000},"page":"307-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia"],"prefix":"10.1007","volume":"24","author":[{"given":"Hiroshi","family":"Matsuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-3650","authenticated-orcid":false,"given":"Eiji","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Tanoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yasutomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"key":"1829_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10157-014-0948-3","volume":"18","author":"K Kimura","year":"2014","unstructured":"Kimura K. Preface: evidence-based clinical practice guidelines for CKD: an abridged English version. Clin Exp Nephrol. 2014;18:339\u201340.","journal-title":"Clin Exp Nephrol."},{"key":"1829_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1291\/hypres.24.691","volume":"24","author":"K Iseki","year":"2001","unstructured":"Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691\u20137.","journal-title":"Hypertens Res."},{"key":"1829_CR3","doi-asserted-by":"publisher","first-page":"e100801","DOI":"10.1371\/journal.pone.0100801","volume":"9","author":"P Zhu","year":"2014","unstructured":"Zhu P, Liu Y, Han L, Xu G, Ran JM. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PLoS ONE. 2014;9:e100801.","journal-title":"PLoS ONE"},{"key":"1829_CR4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.ajkd.2014.04.024","volume":"64","author":"MC Odden","year":"2014","unstructured":"Odden MC, Amadu AR, Smit E, Lo L, Peralta CA. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988\u20131994 and 1999\u20132002. Am J Kidney Dis. 2014;64:550\u20137.","journal-title":"Am J Kidney Dis."},{"key":"1829_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-2369-12-31","volume":"12","author":"M Kawashima","year":"2011","unstructured":"Kawashima M, Wada K, Ohta H, Terawaki H, Aizawa Y. Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: a long-term retrospective cohort study. BMC Nephrol. 2011;12:31.","journal-title":"BMC Nephrol."},{"key":"1829_CR6","unstructured":"Maxwell AJ, Bruinsma KA. Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. J Am Coll Cardiol. 2001;38:1850\u20138."},{"key":"1829_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.redox.2013.05.002","volume":"1","author":"N Cantu-Medellin","year":"2013","unstructured":"Cantu-Medellin N, Kelley EE. Xanthine oxidoreductase-catalyzed reactive species generation: a process in critical need of reevaluation. Redox Biol. 2013;1:353\u20138.","journal-title":"Redox Biol."},{"key":"1829_CR8","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1159\/000345509","volume":"121","author":"LG Sanchez-Lozada","year":"2012","unstructured":"Sanchez-Lozada LG, Lanaspa MA, Cristobal-Garcia M, Garcia-Arroyo F, Soto V, Cruz-Robles D, et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012;121:e71\u2013e7878.","journal-title":"Nephron Exp Nephrol."},{"key":"1829_CR9","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s10157-014-0935-8","volume":"18","author":"T Hosoya","year":"2014","unstructured":"Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol. 2014;18:876\u201384.","journal-title":"Clin Exp Nephrol."},{"key":"1829_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jjcc.2014.12.017","volume":"66","author":"A Sezai","year":"2015","unstructured":"Sezai A, Soma M, Nakata K, Osaka S, Ishii Y, Yaoita H, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). J Cardiol. 2015;66:298\u2013303.","journal-title":"J Cardiol."},{"key":"1829_CR11","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40261-018-0699-0","volume":"38","author":"T Hosoya","year":"2018","unstructured":"Hosoya T, Ishikawa T, Ogawa Y, Sakamoto R, Ohashi T. Multicenter, open-label study of long-term topiroxostat (FYX-051) administration in Japanese Hyperuricemic patients with or without gout. Clin Drug Investig. 2018;38:1135\u201343.","journal-title":"Clin Drug Investig."},{"key":"1829_CR12","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/nep.13177","volume":"23","author":"T Mizukoshi","year":"2018","unstructured":"Mizukoshi T, Kato S, Ando M, Sobajima H, Ohashi N, Naruse T, et al. Renoprotective effects of topiroxostat for hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): a prospective, randomized, multicentre clinical trial. Nephrology (Carlton). 2018;23:1023\u201330.","journal-title":"Nephrology (Carlton)."},{"key":"1829_CR13","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s10157-018-1530-1","volume":"22","author":"T Wada","year":"2018","unstructured":"Wada T, Hosoya T, Honda D, Sakamoto R, Narita K, Sasaki T, et al. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). Clin Exp Nephrol. 2018;22:860\u201370.","journal-title":"Clin Exp Nephrol."},{"key":"1829_CR14","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","volume":"66","author":"D Sircar","year":"2015","unstructured":"Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized placebo-controlled trial. Am J Kidney Dis. 2015;66:945\u201350.","journal-title":"Am J Kidney Dis."},{"key":"1829_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ejphar.2016.03.055","volume":"780","author":"T Nakamura","year":"2016","unstructured":"Nakamura T, Murase T, Nampei M, Morimoto N, Ashizawa N, Iwanaga T, et al. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db\/db mice. Eur J Pharmacol. 2016;780:224\u201331.","journal-title":"Eur J Pharmacol."},{"key":"1829_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/jdi.12870","volume":"10","author":"S Sunagawa","year":"2019","unstructured":"Sunagawa S, Shirakura T, Hokama N, Kozuka C, Yonamine M, Namba T, et al. Activity of xanthine oxidase in plasma correlates with indices of insulin resistance and liver dysfunction in patients with type 2 diabetes mellitus and metabolic syndrome: a pilot exploratory study. J Diabetes Investig. 2019;10:94\u2013103.","journal-title":"J Diabetes Investig."},{"key":"1829_CR17","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72:798\u2013810.","journal-title":"Am J Kidney Dis."},{"key":"1829_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/07853890.2016.1243803","volume":"49","author":"LH Qu","year":"2017","unstructured":"Qu LH, Jiang H, Chen JH. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. Ann Med. 2017;49:142\u201356.","journal-title":"Ann Med."},{"key":"1829_CR19","doi-asserted-by":"crossref","unstructured":"Sampson AL, Singer RF, Walters GD. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev. 2017;10:Cd009460.","DOI":"10.1002\/14651858.CD009460.pub2"},{"key":"1829_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/0886022X.2018.1456463","volume":"40","author":"X Liu","year":"2018","unstructured":"Liu X, Zhai T, Ma R, Luo C, Wang H, Liu L. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2018;40:289\u201397.","journal-title":"Ren Fail."},{"key":"1829_CR21","doi-asserted-by":"crossref","unstructured":"Pisano A, Cernaro V, Gembillo G, D'Arrigo G, Buemi M, Bolignano D. Xanthine Oxidase inhibitors for improving renal function in chronic kidney disease patients: an updated systematic review and meta-analysis. Int J Mol Sci. 2017;18.","DOI":"10.3390\/ijms18112283"},{"key":"1829_CR22","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/j.1464-5491.2011.03472.x","volume":"29","author":"Y Wada","year":"2012","unstructured":"Wada Y, Hamamoto Y, Ikeda H, Honjo S, Kawasaki Y, Mori K, et al. Seasonal variations of urinary albumin creatinine ratio in Japanese subjects with Type 2 diabetes and early nephropathy. Diabet Med. 2012;29:506\u20138.","journal-title":"Diabet Med."}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01829-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-019-01829-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01829-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T01:25:37Z","timestamp":1607995537000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-019-01829-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1829"],"URL":"https:\/\/doi.org\/10.1007\/s10157-019-01829-z","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,16]]},"assertion":[{"value":"15 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The MIE-CKD study was sponsored by Sanwa Kagaku Kenkyusho CO., LTD., which had no role in the data collection or analysis, decision to publish, or preparation of the manuscript. S.N. received lecture fees of more than 500,000 yen from Otsuka Pharma Inc. in 2016. M.I received lecture fees of more than 500,000 yen from Bayer Yakuhin, Ltd., Daiichi Sankyo Co. Ltd. and Mitsubishi Tanabe Pharma Corporation in 2016. The Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, was supported in part by unrestricted research grants of more than 1,000,000 yen from Daiichi Sankyo Co. Ltd., Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., MSD K.K., Astellas Pharma Inc., Takeda Pharmaceutical Company Limited and Pfizer Japan Inc. in 2016. The Division of Hemodialysis Center, Mie University Hospital, was supported in part by unrestricted research grants of more than 1,000,000 yen from Sanwa Kagaku Kenkyusho Co., Ltd., in 2016. No relevant conflicts of interest related to the article were disclosed by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was initially approved by the Medical Research Ethics Review Committee of Mie University Hospital (reference number 2778) and subsequently by the institutional review boards at all other participating hospitals in accordance with the Declaration of Helsinki. This study was registered in the UMIN Clinical Trials Registry (registration ID number: UMIN000016172).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients before enrolment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}